0
0
A virus commonly found in black-eyed peas, known as the cowpea mosaic virus (CPMV), is emerging as a potential breakthrough in cancer immunotherapy, according to new research from the University of California San Diego. The study, recently published in Cell Biomaterials, uncovers why CPMV, unlike other plant viruses, effectively recruits the body’s immune system to attack and destroy cancer cells.
How CPMV Works
In preclinical studies, CPMV demonstrated strong anti-tumor effects in mouse models and even in dogs with cancer. When injected directly into tumors, CPMV therapy triggers an influx of innate immune cells—like neutrophils, macrophages, and natural killer cells—into the tumor site, leading to the destruction of cancer cells. The virus also activates B cells and T cells, creating long-lasting, systemic immune memory that may help the immune system track down cancer elsewhere in the body.
What Makes CPMV Unique?
Researchers compared CPMV to the closely related cowpea chlorotic mottle virus (CCMV), which does not exhibit anti-tumor effects. Both viruses are similarly absorbed by human immune cells, but only CPMV initiates a powerful anti-cancer response. The key appears to be CPMV’s ability to stimulate multiple types of interferons—proteins historically used in early cancer immunotherapy treatments—and its RNA’s unique processing inside mammalian cells. CPMV RNA persists inside immune cells and activates the toll-like receptor 7 (TLR7), a critical switch for priming the body’s anti-tumor defenses, a step that CCMV fails to achieve.
A major advantage of CPMV is its manufacturing process: it can be produced cheaply and sustainably through molecular farming, using only sunlight, soil, and water. This could make immunotherapy more accessible and affordable.
Next Steps
While these findings are promising, the research team—led by chemical and nano engineers Nicole Steinmetz and Anthony Omole—emphasizes that clinical trials in humans are a necessary next step. “We are diligently working toward the next steps to ensure that the most potent lead candidate is selected to achieve anti-tumor efficacy and safety,” said Steinmetz, noting their goal to move CPMV beyond the lab and into the clinic.
“What we found most exciting is that although human immune cells are not infected by CPMV, they respond to it and are reprogrammed toward an activated state, which ultimately trains them to detect and eradicate cancerous cells.” — Anthony Omole, study first author
Disclaimer
This article summarizes recent preclinical research on CPMV as a cancer immunotherapy candidate. CPMV therapy is not yet approved for human use; further studies and clinical trials are required to determine its efficacy and safety for patients. Readers should consult medical professionals before considering any new or experimental treatments.
